MCM
ZYNE

Mainstay Capital Management’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Mainstay Capital Management’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-300
Closed -$2K – 394
2018
Q3 		$2K Hold
300
– – ﹤0.01% 407
2018
Q2 		$3K Hold
300
– – ﹤0.01% 397
2018
Q1 		$2K Buy
+300
New +$3.23K ﹤0.01% 308

Other funds holding ZYNE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCM
Campbell Capital Management Miami, Florida $279M AUM 49.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Mainstay Capital Management's ZYNE Position: Q4 2018 in Review

Mainstay Capital Management sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q4 2018, closing a stake of 300 shares — an estimated $2K sold.

Mainstay Capital Management first reported a position in ZYNE in Q1 2018 and held it in 3 quarters. The position peaked at $3K in Q2 2018. 62 funds tracked by Wall St. Rank hold ZYNE as of Q4 2018.

  • Mainstay Capital Management reported no remaining Zynerba Pharmaceuticals, Inc position as of Q4 2018 after selling out during the quarter.
  • Mainstay Capital Management sold 300 Zynerba Pharmaceuticals, Inc shares in Q4 2018, an estimated $2K.
  • Mainstay Capital Management first reported a position in Zynerba Pharmaceuticals, Inc in Q1 2018 and held it in 3 quarters.
  • Mainstay Capital Management's Zynerba Pharmaceuticals, Inc position peaked at $3K in Q2 2018.
  • 62 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q4 2018.

Based on Mainstay Capital Management's 13F filing for Q4 2018, filed 8 Feb 2019.